Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
- The Deutsche Messe AG in Hannover (Germany) ranks the GENEART AG as one of the best European enterprises in biotechnology and life sciences - The exceptional innovative spirit combined with a high-performance business concept qualified the GENEART AG team for the final - The renowned biotechnology prize will be awarded on October 06, 2008 in Hannover
Regensburg, August 25, 2008 - The GENEART AG is one of three finalists in the "European Biotechnica Award 2008" competition. The award recognizes first rate entrepreneurial accomplishments of European biotechnology companies. Only companies with an exceptional innovative spirit combined with high performance business concepts are awarded with this renowned biotechnology award. The award ceremony is part of the opening celebration at the BIOTECHNICA 2008 on October 06 in Hannover.
GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology has advanced the way synthetic genes are produced by miles since the company was established in 1999. Synthetic genes are needed to develop modern DNA therapeutics, vaccines and industrial enzymes, for example. All genes and gene products distributed by the GENEART AG are "made in Germany", exclusively produced in the GENEART laboratories in Regensburg.
Professor Ralf Wagner, CEO of the GENEART AG, comments: "Our place as a finalist in the 'European Biotechnica Award 2008' competition acknowledges our accomplishments throughout our company history. Based on our sustained investments in research and development, we were able to forge ahead and extend our leadership role in the market. Most of all, our customers in biotechnology as well as in the pharmaceutical and chemical industries profit from our expertise in executing increasingly complex projects, and from our fast extension of production capacities. As a result, time to market intervals for example in the development of therapeutics are reduced significantly."
"With a total of Euro 100,000.00, the 'European Biotechnica Award' is the prize with the highest monetary value and the most important award for small and mid-sized enterprises in the European biotechnology and life sciences", explains Stephan Ph. Kühne, member on the Managing Board of the Deutsche Messe AG, the company inviting to the annual competition.
More information on the Biotechnica Award can be found at www.biotechnica.de/award_d
Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 info@better-orange.de www.better-orange.de
Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.
About GENEART AG In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.
